MannKind Corporation, a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, and Cipla Ltd. announced that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) inhalation powder in adults. The CDSCO decision follows existing approvals in the United States and Brazil.
Achieving approval for Afrezza in India, a country with the second highest burden of diabetes worldwide, is an exciting milestone for MannKind and our partner Cipla,” said Michael Castagna, PharmD, chief executive officer for MannKind Corporation. “We are excited for Cipla to market the first inhaled insulin treatment option for adults living with diabetes in India and expect to prepare product for export by the end of 2025.”
MannKind entered into an exclusive marketing and distribution agreement for Afrezza in India with Cipla Ltd., a global pharmaceutical company, in May 2018. Under the terms of the agreement, Cipla was responsible for obtaining regulatory approvals to distribute Afrezza in India as well as marketing and sales activities. MannKind is responsible for supplying Afrezza to Cipla.
The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycaemic control via a non-injectable and convenient delivery of inhaled insulin,” said Dr. Satish Garg, MBBS, DM, Professor of Medicine and Paediatrics at the Adult Clinic of the Barbara Davis Center for Diabetes of the University of Colorado School of Medicine in Denver.
The International Diabetes Federation (IDF) reported in 2021 that diabetes mellitus affects 537 million adults (20-79 years of age) worldwide, including more than 74 million people in India. IDF estimations are that the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045.
Afrezza (insulin human) inhalation powder is a rapid-acting inhaled human insulin indicated to improve glycaemic control in adults with diabetes mellitus.
Limitations of use: Not recommended for the treatment of diabetic ketoacidosis or in patients that smoke or have recently stopped smoking.
MannKind Corporation focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!